Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Chi-Fu Jeffrey Yang is a thoracic surgeon at Massachusetts General Hospital and an assistant professor of surgery at Harvard Medical School. He received his bachelor's degree in biochemistry from Harvard College and his medical degree at Harvard Medical School. He completed his general surgery residency at Duke and cardiothoracic surgery fellowship at Stanford. 

Lung Cancer Onctalk 2023 - Dr. Jeff Yang
A recorded live event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC).
Author
Chi-Fu Jeffrey Yang, MD - Guest Faculty
Image
Lung Cancer OncTalk 2023

At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 

Dr. Chi-Fu Jeffrey Yang is a thoracic surgeon at Massachusetts General Hospital and an assistant professor of surgery at Harvard Medical School. He received his bachelor's degree in biochemistry from Harvard College and his medical degree at Harvard Medical School. He completed his general surgery residency at Duke and his cardiothoracic surgery fellowship at Stanford. 

Learn more about Dr. Yang here.

To watch the complete playlist click here.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on